Mary Anne  Heino net worth and biography

Mary Heino Biography and Net Worth

CEO of Lantheus
Mary Anne Heino brings to Lantheus 30 years of diverse pharmaceutical industry experience. Joining Lantheus in April 2013 as Chief Commercial Officer, Ms. Heino was promoted to Chief Operating Officer in March 2015 and to President and Chief Executive Officer in August 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing.  Before that, Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson Company, including Vice President Strategic Planning and Competitive Intelligence, Vice President Sales, Executive Director Customer Relationship Management and Senior Director Immunology Marketing. Ms. Heino began her professional career with Janssen Pharmaceutica N.V. as a Sales Representative in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master’s in Business Administration from the Stern School of Business at New York University. She earned a Bachelor’s of Science in Nursing from the City University of New York and a Bachelor’s of Science in Biology from the State University of New York at Stony Brook. She is currently on the Board of Directors for MassMEDIC, an industry association that serves the MedTech community of Massachusetts, and serves on the Executive Committee for the Massachusetts Business Roundtable (MBR).

What is Mary Anne Heino's net worth?

The estimated net worth of Mary Anne Heino is at least $29.39 million as of March 4th, 2024. Ms. Heino owns 251,643 shares of Lantheus stock worth more than $29,389,386 as of July 21st. This net worth evaluation does not reflect any other investments that Ms. Heino may own. Learn More about Mary Anne Heino's net worth.

How do I contact Mary Anne Heino?

The corporate mailing address for Ms. Heino and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Mary Anne Heino's contact information.

Has Mary Anne Heino been buying or selling shares of Lantheus?

Mary Anne Heino has not been actively trading shares of Lantheus within the last three months. Most recently, Mary Anne Heino sold 93,863 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a transaction totalling $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares of the company's stock, valued at $16,434,804.33. Learn More on Mary Anne Heino's trading history.

Who are Lantheus' active insiders?

Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.

Are insiders buying or selling shares of Lantheus?

During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 19 times. They sold a total of 173,715 shares worth more than $12,216,165.11. The most recent insider tranaction occured on July, 15th when CAO Andrea Sabens sold 341 shares worth more than $41,994.15. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.

Information on this page was last updated on 7/15/2024.

Mary Anne Heino Insider Trading History at Lantheus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/4/2024Sell93,863$65.31$6,130,192.53251,643View SEC Filing Icon  
11/13/2023Sell11,780$63.72$750,621.60317,687View SEC Filing Icon  
8/11/2023Sell10,950$68.58$750,951.00329,467View SEC Filing Icon  
3/27/2023Sell44,484$80.77$3,592,972.68419,397View SEC Filing Icon  
3/8/2023Sell10,064$74.70$751,780.80719,397View SEC Filing Icon  
3/6/2023Sell12,189$73.24$892,722.36729,461View SEC Filing Icon  
3/3/2023Sell82,055$73.00$5,990,015.00741,650View SEC Filing Icon  
11/8/2022Sell13,150$57.21$752,311.50672,533View SEC Filing Icon  
5/9/2022Sell12,276$61.19$751,168.44695,115View SEC Filing Icon  
3/3/2022Sell11,173$52.13$582,448.49View SEC Filing Icon  
2/28/2022Sell43,909$46.50$2,041,768.50View SEC Filing Icon  
11/10/2021Sell13,333$30.12$401,589.96View SEC Filing Icon  
4/12/2021Sell19,421$20.66$401,237.86View SEC Filing Icon  
3/5/2021Sell27,157$18.26$495,886.82711,720View SEC Filing Icon  
7/23/2020Sell3,000$16.02$48,060.00604,793View SEC Filing Icon  
7/15/2020Sell22,125$16.01$354,221.25607,793View SEC Filing Icon  
4/27/2020Sell30,033$13.77$413,554.41634,318View SEC Filing Icon  
2/26/2020Sell6,615$17.09$113,050.35549,399View SEC Filing Icon  
2/24/2020Sell9,898$16.06$158,961.88556,014View SEC Filing Icon  
12/20/2019Sell19,260$20.85$401,571.00563,034View SEC Filing Icon  
9/20/2019Sell15,590$25.81$402,377.90582,294View SEC Filing Icon  
9/3/2019Sell25,538$21.21$541,660.98597,884View SEC Filing Icon  
6/20/2019Sell14,340$27.89$399,942.60624,997View SEC Filing Icon  
5/20/2019Sell16,827$23.89$401,997.03637,762View SEC Filing Icon  
4/26/2019Sell29,813$24.86$741,151.18654,589View SEC Filing Icon  
4/12/2019Sell15,799$25.40$401,294.60684,402View SEC Filing Icon  
3/5/2019Sell9,294$23.35$217,014.90709,220View SEC Filing Icon  
2/25/2019Sell9,456$24.06$227,511.36621,326View SEC Filing Icon  
1/30/2019Sell9,564$16.47$157,519.08630,782View SEC Filing Icon  
7/12/2017Sell10,000$18.05$180,500.00592,468View SEC Filing Icon  
6/12/2017Sell10,000$15.39$153,900.00602,468View SEC Filing Icon  
See Full Table

Mary Anne Heino Buying and Selling Activity at Lantheus

This chart shows Mary Anne Heino's buying and selling at Lantheus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lantheus Company Overview

Lantheus logo
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Read More

Today's Range

Now: $116.79
Low: $116.00
High: $118.71

50 Day Range

MA: $86.32
Low: $77.70
High: $123.62

2 Week Range

Now: $116.79
Low: $50.20
High: $126.89


700,926 shs

Average Volume

1,541,326 shs

Market Capitalization

$8.09 billion

P/E Ratio


Dividend Yield